Cagrilintide Research Hub · Evidence Overview

Cagrilintide research evidence: what has actually been studied?

A structured review of cagrilintide research, separating controlled human trials from mechanistic and preclinical evidence.

JD BioWorks Research LibraryPublished: July 15, 2026Last reviewed: July 15, 2026Editorial review: JD BioWorks Research Library

Evidence at a glance

Human evidenceModerate for an investigational compound: randomized phase 2 studies have evaluated cagrilintide alone and with semaglutide in defined populations.

Preclinical evidenceMechanistic work builds on amylin-receptor biology and long-acting analogue design, but product-specific translation depends on the exact molecule and formulation.

Evidence gapLong-term comparative outcomes, broader populations, and evidence independent of sponsor-led development remain limited.

ScopePublished outcomes from drug-development trials do not establish the identity, purity, safety, or equivalence of a separately supplied research material.

Interpretation note: Findings must stay tied to the exact molecule, formulation, model, population, and endpoint studied. A biological signal is not, by itself, proof of safety or effectiveness.

Overview

Cagrilintide is a long-acting amylin analogue developed to activate amylin-receptor pathways. Amylin is co-secreted with insulin and participates in post-meal signaling, gastric emptying, and satiety-related physiology. The name identifies a specific investigational molecule; it should not be used as a generic label for every amylin-related material.

Research background

The best characterized evidence comes from randomized clinical trials in adults with overweight or obesity, including a dose-finding phase 2 study and later combination studies with semaglutide. These trials answer narrow questions about defined drug products, doses, eligibility criteria, and endpoints. They do not validate unrelated preparations or support extrapolation beyond the studied populations.

Findings by research area

Research area	What has been reported	What it does not establish
Dose-finding trials	A 26-week randomized phase 2 trial compared multiple cagrilintide dose groups with placebo and an active comparator.	Long-term outcomes or equivalence to other materials.
Combination research	Randomized studies evaluated cagrilintide co-administered with semaglutide in metabolic-disease populations.	The contribution of cagrilintide outside the tested combination and protocol.
Mechanism	The research rationale is based on sustained amylin-receptor agonism.	That a proposed mechanism predicts an individual outcome.

Human evidence

Human data

The 2021 multicenter dose-finding trial randomized 706 participants to cagrilintide dose groups, 99 to liraglutide, and 101 to placebo. At 26 weeks, the investigators reported dose-related differences in body weight and a higher frequency of gastrointestinal adverse events than placebo. A separate phase 2 trial studied co-administered cagrilintide and semaglutide in participants with type 2 diabetes. These are controlled human data, but interpretation must retain the trial design, population, estimand, titration schedule, and sponsor involvement.

Preclinical evidence

Animal data

Cagrilintide development rests on preclinical pharmacology used to select a long-acting amylin analogue and characterize receptor activity. Such studies can establish target engagement and support dose selection, but animal feeding behavior and energy balance do not reproduce human clinical outcomes.

Laboratory evidence

In-vitro and analytical context

Receptor and cellular assays are useful for comparing potency, selectivity, and signaling. They do not characterize a commercial sample unless the tested sample itself is analytically linked to the study material.

Research limitations

Most mature evidence is sponsor-led drug development.
Results apply to the studied formulations and protocols, not to any material sharing the name.
Trial durations and inclusion criteria limit long-term and broad-population inference.
Combination trials cannot be read as evidence for either component under every condition.

Future research

Useful future work includes longer comparative trials, transparent reporting across diverse populations, independent replication, and clear analytical bridges between test articles used in preclinical and clinical phases.

Primary references

Article record

Research question: What does the published evidence on Cagrilintide show across human, animal, and laboratory research?
Evidence cutoff: July 15, 2026
Article status: Published educational research summary; not independently peer reviewed
Author: JD BioWorks Research Library
Editorial review: JD BioWorks Research Library
Planned review cycle: At least annually, or sooner if material evidence or regulatory information changes

This article summarizes published research for educational and laboratory-information purposes. It is not medical advice, does not provide instructions for personal use, and does not establish that any material is safe or effective for human or veterinary use.

CONTINUE YOUR REVIEW

Next steps for qualified researchers

Use the public documentation resources below, then continue to Research Product Access when you are ready to review the gated catalog.

Search Certificates of Analysis Match available analytical records to the named product, quantity, and lot. Explore Research Guides Review HPLC, LC-MS, purity, identity, storage, and traceability guidance. Get Research Product Access Complete the Research Use Acknowledgment to create an account and receive automatic product access.

For qualified laboratory, analytical, educational, or institutional research only. Not for human or veterinary use.